Towards Selective Inhibition of Histone Deacetylase Isoforms: What Has Been Achieved, Where We Are and What Will Be Next
Citations Over TimeTop 10% of 2013 papers
Abstract
Histone deacetylases (HDACs) are widely studied targets for the treatment of cancer and other diseases. Up to now, over twenty HDAC inhibitors have entered clinical studies and two of them have already reached the market, namely the hydroxamic acid derivative SAHA (vorinostat, Zolinza) and the cyclic depsipeptide FK228 (romidepsin, Istodax) that have been approved for the treatment of cutaneous T-cell lymphoma (CTCL). A common aspect of the first HDAC inhibitors is the absence of any particular selectivity towards specific isozymes. Some of molecules resulted to be “pan”-HDAC inhibitors, while others are class I selective. In the meantime, the knowledge of HDAC biology has continuously progressed. Key advances in the structural biology of various isozymes, reliable molecular homology models as well as suitable biological assays have provided new tools for drug discovery activities. This Minireview aims at surveying these recent developments as well as the design, synthesis and biological characterization of isoform-selective derivatives.
Related Papers
- → Targeted Cancer Therapy: Giving Histone Deacetylase Inhibitors All They Need To Succeed(2012)387 cited
- Potential non-oncological applications of histone deacetylase inhibitors.(2011)
- → Current Trends in the Development of Histone Deacetylase Inhibitors: A Review of Recent Patent Applications(2012)20 cited
- → The Emerging Role of Histone Deacetylase Inhibitors in Treating T-cell Lymphomas(2010)11 cited
- Progress in clinical trial of histone deacetylase (HDAC) inhibitors for non-small cell lung cancers*(2014)